Peripheral Blood CD19+CD27+ Memory B Cells, Frozen
Human CD19+CD27+ memory B cells are isolated from peripheral blood mononuclear cells. Cells expressing CD2, CD14, CD16, CD36, CD43, and CD235a are depleted from the mononuclear cell population using immunomagnetic particles leaving an enriched CD19+ fraction. CD27+ cells are then enriched from the CD19+ fraction using immunomagnetic anti-CD27 particles leaving purified CD19+CD27+ memory B cells. Isolated cells are characterized by flow cytometry before cryopreservation to ensure a highly pure and viable cell population.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies. By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.

Description
Peripheral blood CD19+CD27+ memory B cells become active in the wake of a primary infection from a particular antigen. Memory B cells can persist for years or even a lifetime after an encounter with an antigen. The presence of these cells allows for a faster antibody response if the host comes into contact with the same pathogen.
Additional information
Anticoagulant | |
---|---|
Format | |
Grade | |
Species | |
Cell and Tissue Source | |
Disease State | |
Donor Attributes |
Product Information Sheet
Figure 1. Representative flow data of peripheral blood enriched CD19+CD27+ memory B cells prior to cryopreservation.